Neoadjuvant TAMP therapy for borderline resectable pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study tests a combination treatment given before surgery to shrink pancreatic tumors and improve the chance of complete removal. It is for people with borderline resectable pancreatic cancer, meaning the tumor is close to major blood vessels but may still be removable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with pancreatic ductal adenocarcinoma (the most common type of pancreatic cancer).
- Your tumor is considered borderline resectable, meaning it is close to important blood vessels but surgery might still be possible.
- You have not had any previous treatment for this cancer, such as chemotherapy, radiation, or surgery.
- You are 18 years or older.
- You are in good overall health (able to carry out daily activities) — specifically, your performance status is 0 or 1.
- You are able to understand and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four drugs given before surgery to shrink pancreatic tumors that are borderline resectable or high-risk. The goal is to make surgery more effective and improve outcomes.
This trial studies whether giving chemotherapy before surgery, and possibly adding a focused high-dose radiation treatment, can improve outcomes for people with borderline resectable pancreatic cancer. It aims to shrink or control the cancer and help more patients get to surgery safely.
This study tests a new treatment approach for pancreatic cancer that is on the edge of being removable with surgery. It combines radiation therapy with chemotherapy and an immunotherapy drug (a PD-1 inhibitor) plus a thymalfasin (a medication that helps regulate the immune system) to see if this combination can help shrink the tumor before surgery.
This study tests giving chemotherapy before surgery for pancreatic cancer that is borderline removable. The chemo is chosen based on your tumor's genetic signature, which may make the treatment more effective and help shrink the tumor enough for successful surgery.
This trial tests a new treatment, PTM-101, placed during a laparoscopy procedure for people with pancreatic cancer that can be removed with surgery. It aims to see if adding this treatment before standard chemotherapy helps improve outcomes.
This trial tests a combination of drugs (nimotuzumab, nab-paclitaxel, and gemcitabine) given before and after surgery for pancreatic cancer that is either removable or borderline removable but has high-risk features. The goal is to see if this approach improves outcomes.
Hear when a new Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.